Richard James Whitley - Net Worth and Insider Trading

Richard James Whitley Net Worth

The estimated net worth of Richard James Whitley is at least $2 Million dollars as of 2024-04-25. Richard James Whitley is the Director of Gilead Sciences Inc and owns about 25,135 shares of Gilead Sciences Inc (GILD) stock worth over $2 Million. Richard James Whitley is also the Director of Virios Therapeutics Inc and owns about 700 shares of Virios Therapeutics Inc (VIRI) stock worth over $298. Details can be seen in Richard James Whitley's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Richard James Whitley has not made any transactions after 2022-12-08 and currently still holds the listed stock(s).

Transaction Summary of Richard James Whitley

To

Richard James Whitley Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Richard James Whitley owns 2 companies in total, including Gilead Sciences Inc () , and Virios Therapeutics Inc () .

Click here to see the complete history of Richard James Whitley’s form 4 insider trades.

Insider Ownership Summary of Richard James Whitley

Ticker Comapny Transaction Date Type of Owner
Gilead Sciences Inc 2019-05-01 director
Virios Therapeutics Inc 2022-12-08 director

Richard James Whitley Latest Holdings Summary

Richard James Whitley currently owns a total of 2 stocks. Among these stocks, Richard James Whitley owns 25,135 shares of Gilead Sciences Inc (GILD) as of May 1, 2019, with a value of $2 Million and a weighting of 99.98%. Richard James Whitley also owns 700 shares of Virios Therapeutics Inc (VIRI) as of December 8, 2022, with a value of $298 and a weighting of 0.02%.

Latest Holdings of Richard James Whitley

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
GILD Gilead Sciences Inc 2019-05-01 25,135 67.08 1,686,056
VIRI Virios Therapeutics Inc 2022-12-08 700 0.43 298

Holding Weightings of Richard James Whitley


Richard James Whitley Form 4 Trading Tracker

According to the SEC Form 4 filings, Richard James Whitley has made a total of 1 transactions in Gilead Sciences Inc (GILD) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in Gilead Sciences Inc is the sale of 9,534 shares on May 1, 2019, which brought Richard James Whitley around $619,901.

According to the SEC Form 4 filings, Richard James Whitley has made a total of 3 transactions in Virios Therapeutics Inc (VIRI) over the past 5 years, including 2 buys and 1 sells. The most-recent trade in Virios Therapeutics Inc is the sale of 1,800 shares on December 8, 2022, which brought Richard James Whitley around $468.

Insider Trading History of Richard James Whitley

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Richard James Whitley Trading Performance

GuruFocus tracks the stock performance after each of Richard James Whitley's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Richard James Whitley is -13.69%. GuruFocus also compares Richard James Whitley's trading performance to market benchmark return within the same time period. The performance of stocks bought by Richard James Whitley within 3 months outperforms 0 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Richard James Whitley's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Richard James Whitley

Average Return

Outperforming Transactions

Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 12.92 -13.69 -27.11 -95.4 -68.59
Relative Return to S&P 500(%) 18.47 -8.55 -8.21 -77.55 -68.75

Richard James Whitley Ownership Network

Ownership Network List of Richard James Whitley

No Data

Ownership Network Relation of Richard James Whitley


Richard James Whitley Owned Company Details

What does Gilead Sciences Inc do?

Who are the key executives at Gilead Sciences Inc?

Richard James Whitley is the director of Gilead Sciences Inc. Other key executives at Gilead Sciences Inc include Chief Medical Officer Merdad Parsey , EVP & Chief Financial Officer Andrew D Dickinson , and Chief Commercial Officer Johanna Mercier .

Gilead Sciences Inc () Insider Trades Summary

Over the past 18 months, Richard James Whitley made no insider transaction in Gilead Sciences Inc (). Other recent insider transactions involving Gilead Sciences Inc () include a net sale of 34,326 shares made by Merdad Parsey , a net sale of 15,000 shares made by Andrew D Dickinson , and a net sale of 22,671 shares made by Diane E. Wilfong .

In summary, during the past 3 months, insiders sold 12,230 shares of Gilead Sciences Inc () in total and bought 0 shares, with a net sale of 12,230 shares. During the past 18 months, 80,239 shares of Gilead Sciences Inc () were sold and 0 shares were bought by its insiders, resulting in a net sale of 80,239 shares.

Gilead Sciences Inc ()'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Gilead Sciences Inc Insider Transactions

No Available Data

Richard James Whitley Mailing Address

Above is the net worth, insider trading, and ownership report for Richard James Whitley. You might contact Richard James Whitley via mailing address: Uab, Chb 303, 1600 7th Avenue South, Birmingham Al 35233-1711.

Discussions on Richard James Whitley

No discussions yet.